Folate-PEG-appended dendrimer conjugate with α-cyclodextrin as a novel cancer cell-selective siRNA delivery carrier.

We previously reported that of the various polyamidoamine (PAMAM) STARBURST dendrimer (generation 3, G3) (dendrimer) conjugates with cyclodextrins (CyDs), the dendrimer (G3) conjugate with α-CyD having an average degree of substitution of 2.4 (α-CDE (G3)) has the greatest potential for a novel carrier for siRNA in vitro and in vivo. To improve the siRNA transfer activity and the lack of target specificity of α-CDE (G3), we prepared folate-polyethylene glycol (PEG)-appended α-CDEs (G3) (Fol-PαCs) with various degrees of substitution of folate (DSF) and evaluated their siRNA transfer activity to folate receptor (FR)-overexpressing cancer cells in vitro and in vivo. Of the three Fol-PαCs (G3, DSF 2, 4 and 7), Fol-PαC (G3, DSF 4) had the highest siRNA transfer activity in KB cells (FR-positive). Fol-PαC (G3, DSF 4) was endocytosed into KB cells through FR. No cytotoxicity of the siRNA complex with Fol-PαC (G3, DSF 4) was observed in KB cells (FR-positive) or A549 cells (FR-negative) up to the charge ratio of 100/1 (carrier/siRNA). In addition, the siRNA complex with Fol-PαC (G3, DSF 4) showed neither interferon response nor inflammatory response. Importantly, the siRNA complex with Fol-PαC (G3, DSF 4) tended to show the in vivo RNAi effects after intratumoral injection and intravenous injection in tumor cells-bearing mice. The FITC-labeled siRNA and TRITC-labeled Fol-PαC (G3, DSF 4) were actually accumulated in tumor tissues after intravenous injection in the mice. In conclusion, the present results suggest that Fol-PαC (G3, DSF 4) could potentially be used as a FR-overexpressing cancer cell-selective siRNA delivery carrier in vitro and in vivo.

[1]  T. Higashi,et al.  Inhibitory effect of siRNA complexes with polyamidoamine dendrimer/α-cyclodextrin conjugate (generation 3, G3) on endogenous gene expression. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[2]  Won Jong Kim,et al.  Polymers in small-interfering RNA delivery. , 2011, Nucleic acid therapeutics.

[3]  N. Svrzikapa,et al.  In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR) , 2010, Silence.

[4]  Y. Oh,et al.  Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Keiichi Motoyama,et al.  Recent Findings Concerning PAMAM Dendrimer Conjugates with Cyclodextrins as Carriers of DNA and RNA , 2009, Sensors.

[6]  D. Thompson,et al.  Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide , 2009, Molecular Cancer Therapeutics.

[7]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[8]  Hidetoshi Arima,et al.  Evaluation of polyamidoamine dendrimer/alpha-cyclodextrin conjugate (generation 3, G3) as a novel carrier for small interfering RNA (siRNA). , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[9]  F. Hirayama,et al.  Enhancement of gene transfer activity mediated by mannosylated dendrimer/alpha-cyclodextrin conjugate (generation 3, G3). , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Haliza Katas,et al.  Development and characterisation of chitosan nanoparticles for siRNA delivery. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[11]  K. Ono,et al.  Transferrin-loaded nido-carborane liposomes: tumor-targeting boron delivery system for neutron capture therapy. , 2006, Bioconjugate chemistry.

[12]  A. Klippel,et al.  A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium , 2006, Gene Therapy.

[13]  P. Whittaker,et al.  RNA interference: From gene silencing to gene-specific therapeutics , 2005, Pharmacology & Therapeutics.

[14]  Hidetoshi Arima,et al.  Improvement of gene delivery mediated by mannosylated dendrimer/α-cyclodextrin conjugates , 2005 .

[15]  P. Low,et al.  Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. , 2005, Analytical biochemistry.

[16]  T. Irimura,et al.  Antitumor Activity of Small Interfering RNA/Cationic Liposome Complex in Mouse Models of Cancer , 2004, Clinical Cancer Research.

[17]  S. Asano,et al.  CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. , 2004, Blood.

[18]  T. Suhara,et al.  Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. , 2004, International journal of pharmaceutics.

[19]  Satyajit Mayor,et al.  Folate receptor endocytosis and trafficking. , 2004, Advanced drug delivery reviews.

[20]  R. Schiffelers,et al.  Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[21]  F. Hirayama,et al.  In vitro and in vivo gene transfer by an optimized alpha-cyclodextrin conjugate with polyamidoamine dendrimer. , 2003, Bioconjugate chemistry.

[22]  M. Monsigny,et al.  Glycofection: facilitated gene transfer by cationic glycopolymers , 2003, Cellular and Molecular Life Sciences CMLS.

[23]  F. Hirayama,et al.  Effects of structure of polyamidoamine dendrimer on gene transfer efficiency of the dendrimer conjugate with alpha-cyclodextrin. , 2002, Bioconjugate chemistry.

[24]  Philip S Low,et al.  Folate-mediated delivery of macromolecular anticancer therapeutic agents. , 2002, Advanced drug delivery reviews.

[25]  T. Tuschl,et al.  Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate , 2001, The EMBO journal.

[26]  E. Moss,et al.  RNA interference: It's a small RNA world , 2001, Current Biology.

[27]  F. Hirayama,et al.  Enhancement of gene expression by polyamidoamine dendrimer conjugates with alpha-, beta-, and gamma-cyclodextrins. , 2001, Bioconjugate chemistry.

[28]  T. Tuschl,et al.  RNA Interference and Small Interfering RNAs , 2001, Chembiochem : a European journal of chemical biology.

[29]  C. Leamon,et al.  Folate copolymer-mediated transfection of cultured cells. , 1999, Bioconjugate chemistry.

[30]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[31]  M. Ishiyama,et al.  A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. , 1996, Biological & pharmaceutical bulletin.

[32]  P. Elwood,et al.  Studies of the role of a particulate folate-binding protein in the uptake of 5-methyltetrahydrofolate by cultured human KB cells. , 1985, The Journal of biological chemistry.

[33]  Hong Yang,et al.  Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene , 2005, Nature Medicine.

[34]  J. G. Patton,et al.  siRNA therapeutics: big potential from small RNAs , 2005, Gene Therapy.

[35]  N. Kosaka,et al.  Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. , 2004, Nucleic acids research.

[36]  P. Low,et al.  Folate-mediated targeting: from diagnostics to drug and gene delivery. , 2001, Drug discovery today.

[37]  P. Low,et al.  Folate-mediated targeting of therapeutic and imaging agents to cancers. , 1998, Critical reviews in therapeutic drug carrier systems.